Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
170.94
-0.24 (-0.14%)
Nov 28, 2025, 4:00 PM EST - Market closed
Repligen Revenue
Repligen had revenue of $188.81M in the quarter ending September 30, 2025, with 21.91% growth. This brings the company's revenue in the last twelve months to $707.89M, up 11.74% year-over-year. In the year 2024, Repligen had annual revenue of $634.44M with 0.33% growth.
Revenue (ttm)
$707.89M
Revenue Growth
+11.74%
P/S Ratio
13.57
Revenue / Employee
$398,138
Employees
1,778
Market Cap
9.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
| Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
| Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
| Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
| Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RGEN News
- 2 days ago - Repligen Corporation to Present at Evercore Healthcare Conference - GlobeNewsWire
- 10 days ago - Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 14 days ago - Repligen: Rare Growth In The Biopharma Supplies Industry - Seeking Alpha
- 17 days ago - Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 18 days ago - Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance - GlobeNewsWire